Food and Drug Administration (FDA)

documents

Benchmarking Dissent Processes and Best Practices

letters

POGO Opposes Califf Nomination Due to Conflicts of Interest POGO Urges Senate to Vote Against Nominee to the FDA POGO Asks President to Withdraw FDA Nominee POGO Letter to Associate Commissioner Warner, FDA, Questioning FDA's Handling of Conflicts of Interest on FDA Advisory Committees POGO and Partners Oppose House Bill that Allows FDA More Secrecy POGO and Groups Support Better Information on Clinical Trials POGO and Partners Oppose FDA Secrecy POGO Letter: FDA Advisors on Yaz and Yasmin Have Industry Ties POGO Letter Urges FDA Not to Weaken Conflict of Interest Standards at Center for Drug Evaluation and Research POGO Letter to FDA Commissioner Hamburg Concerning the Potentially Dangerous Interaction of the Drugs Seroquel and Methodone POGO Asks DHHS Secretary Sebelius to Reinvestigate FDA's Negligent Oversight of Unsafe Medical Devices POGO Letter to FDA Commissioner Margaret Hamburg Regarding Potentially Dangerous Drug Interaction Invovling Seroquel and Methadone POGO's letter to Deputy HHS IG on FDA's CDRH's low standard of medical devices approval The Finances Of FDA Advisory Committee Members: If Information Must Be Withheld, Let It Be Done Openly POGO's letter to Commissioner Hamburg regarding medical devices POGO Letter to FDA's Daniel Schultz MD regarding a policy decision by CDRH to discontinue inspections of nonclinical laboratories POGO Asks FDA Head to Have Deadly Syringe Incident Investigated POGO letter to FDA's Daniel Schultz MD regarding the lack of GLP inspections POGO Follow-up letter to CDRH Director Daniel Schultz POGO Letter to CDRH Director Daniel Schultz regarding a series of questions about the apparent decision not to enforce the GLP regulation

Latest

Avoiding the Subject: On Pfizer Vaccine Quality Control, FDA Says Less than European Counterpart

investigation | March 19, 2021

Latest

Hearing Without Listening

analysis | December 16, 2020

Big Pharma, Oil Dominate List of Federal Contractors Most Penalized for Misconduct

analysis | November 12, 2015
FDA Approves Antidote for Pradaxa, Calls It “Necessary”

analysis | October 20, 2015
Drug Problems: Dangerous Decision-Making at the FDA

investigation | October 15, 2015
FDA Surveillance Threatened Whistleblowers

analysis | February 28, 2014
POGO's Angela Canterbury testifies on “Limitless Surveillance at the FDA: Protecting the Rights of Federal Whistleblowers”

testimony | February 26, 2014
In Bed with Big Pharma? Industry Liaisons Raise Questions at the FDA

investigation | January 12, 2012
Powerful Leader Takes Command of a Battered FDA: Irresistible Force Meets Immovable Object

analysis | May 19, 2009